AMENDMENTS TO THE CLAIMS – Marked up version

Claims 5, 6, 8, 9, 11, 12, 14-23, 25-27 and 29 are pending.

The following list of claims will replace prior versions and listing of claims in the application:

1-4. (Cancelled)

5. (Currently Amended) A method of treating sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D_4 receptor agonist wherein said selective dopamine D_4 receptor agonist is selected from the group consisting of N-{[4-(2-cyanophenyl)-1-piperazinyl]methyl}-3-methylbenzamide and 5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-indole or a pharmaceutically acceptable salt thereof.

6. (Currently Amended) A method of treating male sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D_4 receptor agonist wherein said selective dopamine D_4 receptor agonist is selected from the group consisting of N-{[4-(2-cyanophenyl)-1-piperazinyl]methyl}-3-methylbenzamide and 5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-indole or a pharmaceutically acceptable salt thereof.

7. (Cancelled)

8. (Currently Amended) A method of treating male erectile dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D_4 receptor agonist wherein said selective dopamine D_4 receptor agonist is selected from the group consisting of N-{[4-(2-cyanophenyl)-1-piperazinyl]methyl}-3-methylbenzamide and 5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-indole or a pharmaceutically acceptable salt thereof.

9. ~~(Original) The method of claim 6 wherein said selective dopamine D_4 receptor agonist is N-{[4-(2-cyanophenyl)-1-piperazinyl]methyl}-3-methylbenzamide or a pharmaceutically acceptable salt thereof.~~

10. (Cancelled)

~~11. (Original) The method of claim 8 wherein said selective dopamine D_4 receptor agonist is N-{[4-(2-cyanophenyl)-1-piperazinyl]methyl}-3-methylbenzamide or a pharmaceutically acceptable salt thereof.~~

~~12. (Original) The method of claim 6 wherein said selective dopamine D_4 receptor agonist is 5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-indole or a pharmaceutically acceptable salt thereof~~.

13. (Cancelled)

~~14. (Original) The method of claim 8 wherein said selective dopamine D_4 receptor agonist is 5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-indole or a pharmaceutically acceptable salt thereof.~~

~~15. (Previously Amended) The method of claim 5 wherein said selective dopamine D_4 receptor agonist is 25 fold more selective for the D_4 receptor than for the D_2 receptor.~~

~~16. (Previously Amended) The method of claim 5 wherein said selective dopamine D_4 receptor agonist is 50 fold more selective for the D_4 receptor than for the D_2 receptor.~~

~~17. (Previously Amended) The method of claim 5 wherein said selective dopamine D_4 receptor agonist is 100 fold more selective for the D_4 receptor than for the D_2 receptor.~~

~~18. (Previously Amended) The method of claim 5 wherein said selective dopamine D_4 receptor agonist is 200 fold more selective for the D_4 receptor than for the~~ D_2 receptor.

~~19. (Previously Amended) The method of claim 5 wherein said selective dopamine D_4 receptor agonist is 300 fold more selective for the D_4 receptor than for the D_2 receptor.~~

~~20. (Previously Amended) The method of claim 5 wherein said selective dopamine D_4 receptor agonist is 500 fold more selective for the D_4 receptor than for the D_2 receptor.~~

~~21. (Previously Amended) The method of claim 5 wherein said selective dopamine D_4 receptor agonist is 1000 fold more selective for the D_4 receptor than for the D_2 receptor.~~

~~22. (Original) A method of treating sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D_4 receptor agonist or a pharmaceutically acceptable salt thereof wherein said agonist does not cause significant emesis.~~

~~23. (Currently amended) A method of treating male sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D_4 receptor agonist or a~~

~~pharmaceutically acceptable salt thereof thereof wherein said agonist does not cause significant emesis.~~

24. (Cancelled)

~~25. (Currently amended) A method of treating male erectile dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D_4 receptor agonist or a pharmaceutically acceptable salt thereof thereof wherein said agonist does not cause significant emesis.~~

26. (Currently Amended) A method of treating sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D_4 receptor agonist wherein said selective dopamine D_4 receptor agonist is selected from the group consisting of N-{[4-(2-cyanophenyl)-1-piperazinyl]methyl}-3-methylbenzamide and 5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-indole or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

27. (Currently Amended) A method of treating male sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D_4 receptor agonist wherein said selective dopamine D_4 receptor agonist is selected from the group consisting of N-{[4-(2-cyanophenyl)-1-piperazinyl]methyl}-3-methylbenzamide and 5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-indole or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

28. (Cancelled)

29. (Currently Amended) A method of treating male erectile dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D_4 receptor agonist wherein said selective dopamine D_4 receptor agonist is selected from the group consisting of N-{[4-(2-cyanophenyl)-1-piperazinyl]methyl}-3-methylbenzamide and 5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-indole or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

30. (Cancelled)